Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD79B

CD79B

Brief Information

Name:B-cell antigen receptor complex-associated protein beta chain
Target Synonym:B-Cell Antigen Receptor Complex-Associated Protein Beta Chain,B29,Immunoglobulin-associated B29 protein,Ig-beta,B-cell-specific glycoprotein B29,CD79B,CD79b Molecule,CD79b Molecule, Immunoglobulin-Associated Beta,IGB,CD79B Antigen (Immunoglobulin-Associated Beta),CD79b Antigen,AGM6
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CDB-H82E3-ELISA
Biotinylated Human CD79B, His,AvitagBiotinylated Human CD79B, His,Avitag (Cat. No. CDB-H82E3) ELISA bioactivity

Immobilized Biotinylated Human CD79B, His,Avitag (Cat. No. CDB-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD79B (Polatuzumab) Humanized Antibody with a linear range of 0.1-2 ng/mL (Routinely tested).

CDB-C52H3-MALS-HPLC
Cynomolgus CD79B, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus CD79B, His Tag (Cat. No. CDB-C52H3) is more than 90% and the molecular weight of this protein is around 20-40 kDa verified by SEC-MALS.

  • Background
    B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

CD79b,B29,IGB,Ig-beta

Background

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Polatuzumab vedotin RG-7596; RO-5541077; RO-5541077-000; FCU-2711; DCDS-4501A Approved Genentech Inc, Seattle Genetics Polivy Japan Lymphoma, Large B-Cell, Diffuse F. Hoffmann-La Roche Ag 2019-06-10 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NBT-508 Phase 1 Clinical Newbio Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
PRV-3279 MGD-010; PRV-3279; CD32BxCD79B Phase 2 Clinical Macrogenics Drug-Related Side Effects and Adverse Reactions Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message